AnalystsSalim Syed
Salim Syed's Stock Forecasts

Analyst Ranking
Bottom 10%
#4827 out of 5312 analysts
Average Return
-1.44%
Win Rate
47%37 out of 78
Risk vs Reward
Poor
Good

Salim Syed's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Nkarta IncNKTX
+149.75%$1.99$4.97
2023-08-13 -
2024-08-13
Strong Buy
Bridgebio Pharma IncBBIO
+149.26%$11.47$28.59
2022-08-23 -
2023-08-23
Strong Buy
Cytokinetics IncCYTK
+145.24%$31.32$76.81
2025-05-28 -
2026-05-28
Buy
Bridgebio Pharma IncBBIO
+105.55%$13.52$27.79
2023-05-07 -
2024-05-07
Strong Buy
Bridgebio Pharma IncBBIO
+89.59%$35.17$66.68
2020-02-18 -
2021-02-19
Strong Buy

Salim Syed's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Cytokinetics IncCYTK
8Buy$118.00+43.57%Maintains
3 days ago
Bridgebio Pharma IncBBIO
10Buy$96.00+36.67%Maintains
11 days ago
Amgen IncAMGN
7Hold$303.00-15.44%Maintains
11 days ago
Biogen IncBIIB
15Buy$221.00+2.30%Maintains
12 days ago
Assembly Biosciences IncASMB
3Buy$45.00+68.29%Maintains
12 days ago
Enliven Therapeutics IncELVN
3Buy$62.00+23.80%Maintains
25 days ago
Century Therapeutics IncIPSC
1Buy$8.00+244.83%Initiates Coverage On
a month ago
Sutro Biopharma IncSTRO
1Buy$50.00+63.83%Initiates Coverage On
2 months ago
Autolus Therapeutics PLCAUTL
1Buy$10.00+521.12%Maintains
3 months ago
Syndax Pharmaceuticals IncSNDX
1Buy$43.00+101.78%Maintains
3 months ago
Nkarta IncNKTX
9Buy$12.00+324.03%Maintains
3 months ago
Wave Life Sciences LtdWVE
6Buy$27.00+363.12%Maintains
3 months ago
Maze Therapeutics IncMAZE
1Buy$97.00+241.19%Initiates Coverage On
4 months ago
Incyte CorpINCY
1Buy$121.00+6.37%Upgrades
7 months ago
Gilead Sciences IncGILD
6Buy$117.00N/AMaintains
a year ago
Vaxcyte IncPCVX
3Buy$163.00N/AMaintains
2 years ago
Atara Biotherapeutics IncATRA
4Buy$18.00N/AUpgrades
2 years ago
Crispr Therapeutics AgCRSP
3Strong Buy$99.00N/AMaintains
2 years ago
Unity Biotechnology IncUNBX
5Strong Buy$6.00N/AMaintains
3 years ago
Coherus Oncology IncCHRS
3Strong Buy$21.00N/AMaintains
4 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.